DLBCL

This early-stage study is testing a new type of cell therapy called P-CD19CD20-ALLO1 for people with certain B-cell cancers (like diffuse large B-cell lymphoma) that have come back or not responded to standard treatments. The therapy uses donor immune cells that are specially des…

This study tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults whose primary central nervous system lymphoma (a type of brain cancer) has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and improve surv…

This study tests whether giving a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 participants will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the sa…

This study looks at a new way of giving standard chemotherapy (R-CHOP) to older adults aged 75 and up with diffuse large B-cell lymphoma. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. About 27 participants will receive t…

This study tests a combination of the targeted drug ibrutinib with standard chemotherapy (R-CHOP) in 75 adults under 65 with a specific, aggressive type of lymphoma called ABC-DLBCL. After initial treatment, those who respond well continue ibrutinib alone for 18 months to help ke…

This study tests a new combination of drugs for people aged 75 and older with a type of blood cancer called DLBCL. The treatment pairs a targeted therapy (polatuzumab vedotin) with a lower-dose chemotherapy regimen (R-miniCHP) to see if it can keep the cancer from growing longer …

This study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent cancer from returning in people with high-risk diffuse large B-cell lymphoma. About 109 adults aged 18-75 who achieved complete remission after initial treatment will …

This study tests a new drug called epcoritamab (GEN3013) in people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is an antibody that helps the immune system attack cancer cells. The trial aims to find the best dose, check for side effects, a…

This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…